Mumps measles rubella vaccine | |
| Combination of | |
|---|---|
| Measles vaccine | Vaccine |
| Mumps vaccine | Vaccine |
| Rubella vaccine | Vaccine |
| Clinical data | |
| Trade names | M-M-R II, Priorix, Tresivac, Trimovax, others |
| Other names | MPR vaccine |
| AHFS/Drugs.com | Multum Consumer Information |
| ATC code | |
| Legal status | |
| Legal status |
|
| | |
The MMR vaccine is a vaccine against measles, mumps, and rubella (German measles).
The first dose is given to children around 9 to 15 months of age, with a second dose at 15 months o 6 years of age, with at least 4 weeks between the doses. After two doses 97% of people are protected against measles, 88% against mumps, and at least 97% against rubella.
The World Health Organisation sets a target of 95% needed to achieve and sustain measles elimination. In 2020/1 only 85.5% of five-year-olds in England were vaccinated.
The vaccine is also recommended in those who do not have evidence of immunity, and those with well controlled HIV/AIDS. It is given by injection.